Dashboard
Manage Tickers

LTRNLantern Pharma Inc.

Nasdaq lanternpharma.com


$ 3.97 $ 0.05 (1.24 %)    

Friday, 30-Aug-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 476.00 $ 5.61 (1.19 %)
DIA $ 416.44 $ 2.30 (0.56 %)
SPY $ 563.62 $ 5.33 (0.95 %)
TLT $ 96.60 $ -1.04 (-1.07 %)
GLD $ 231.30 $ -1.66 (-0.71 %)
$ 4.09
$ 4.05 x 100
-- x --
-- - --
$ 2.38 - $ 11.99
26,087
na
44.03M
$ 1.18
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-18-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-20-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-03-2022 03-31-2022 10-Q
11 03-10-2022 12-31-2021 10-K
12 11-01-2021 09-30-2021 10-Q
13 07-29-2021 06-30-2021 10-Q
14 05-03-2021 03-31-2021 10-Q
15 03-10-2021 12-31-2020 10-K
16 10-29-2020 09-30-2020 10-Q
17 07-30-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

watching-lantern-pharma-zacks-small-cap-research-gives-stock-26-price-valuation
Watching Lantern Pharma; Zacks Small Cap R...
08/12/2024 14:01:27

https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08122024_LTRN_Vandermosten.pdf

lantern-pharma-q2-2024-gaap-eps-046-beats-055-estimate
Lantern Pharma Q2 2024 GAAP EPS $(0.46) Be...
08/08/2024 20:45:26

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.55...

lantern-pharma-announces-significant-advancement-in-preclinical-synergy-of-lp-184-with-checkpoint-inhibitors-to-present-data-at-immuno-oncology-summit-2024
Lantern Pharma Announces Significant Advan...
08/07/2024 13:31:40

lantern-pharma-shares-clinical-update-from-ongoing-phase-2-harmonic-clinical-trial-for-never-smokers-with-advanced-nsclc-including-an-86-clinical-benefit-rate-in-the-initial-patient-cohort
Lantern Pharma Shares Clinical Update From...
08/05/2024 12:01:16

The Phase 2 HARMONIC™ study is designed for never smokers with lung adenocarcinoma with the objective to overcome driver mutati...

lantern-pharma-achieves-milestone-towards-development-of-molecular-diagnostic-for-use-in-oncology-clinical-trials-for-patient-selection-and-stratification-with-drug-candidate-lp-184--confirmed-ptgr1-as-a-key-biomarker-that-it-intends-to-use-to-optimize-patient-selection-based-on-potential-tumor-sensitivity-to-the-drug-candidate-lp-184
Lantern Pharma Achieves Milestone Towards ...
07/10/2024 12:35:52

Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine le...

lantern-estimates-that-lp-284-can-have-the-potential-to-improve-outcomes-for-40000-to-80000-patients-with-blood-cancers-annually-with-a-global-annual-market-potential-of-4b
Lantern Estimates That LP-284 Can Have The...
06/12/2024 11:39:58

lantern-pharma-announced-that-the-japan-patent-office-has-issued-a-certificate-of-patent-for-composition-of-matter-covering-drug-candidate-lp-284
Lantern Pharma Announced That The Japan Pa...
06/12/2024 11:34:09

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
05/13/2024 20:31:07

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
05/10/2024 20:31:10

lantern-pharma-q1-2024-gaap-eps-051-misses-043-estimate
Lantern Pharma Q1 2024 GAAP EPS $(0.51) Mi...
05/09/2024 21:02:26

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0....

oregon-therapeutics--lantern-pharma-launch-strategic-ai-collaboration-to-optimize-development-of-first-in-class-drug-candidate-xce853--a-potent-inhibitor-of-cancer-metabolism
Oregon Therapeutics & Lantern Pharma Launc...
05/06/2024 07:00:45

Lantern Pharma Inc. (NASDAQ:LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, toda...

hc-wainwright--co-reiterates-neutral-on-lantern-pharma
HC Wainwright & Co. Reiterates Neutral on ...
04/25/2024 10:36:24

HC Wainwright & Co. analyst Emily Bodnar reiterates Lantern Pharma (NASDAQ:LTRN) with a Neutral.

lantern-pharmashares--are-trading-higher-after-the-company-was-approved-to-expand-its-harmonic-clinical-trial-for-non-small-cell-lung-cancer-in-never-smokers-into-japan-and-taiwan
Lantern Pharmashares are trading higher a...
04/22/2024 12:29:08

lantern-pharma-approved-to-expand-harmonic-clinical-trial-for-non-small-cell-lung-cancer-in-never-smokers-into-japan-and-taiwan
Lantern Pharma Approved To Expand Harmonic...
04/22/2024 12:13:06

never smokers – a growing and unaddressed patient population.Dr. Yashushi Goto a leading lung cancer clinician-scientist at the...

why-wang--lee-group-shares-are-trading-higher-by-38-here-are-20-stocks-moving-premarket
Why Wang & Lee Group Shares Are Trading Hi...
04/19/2024 09:45:48

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
04/11/2024 16:31:52

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
03/19/2024 17:31:02

recap-lantern-pharma-q4-earnings
Recap: Lantern Pharma Q4 Earnings
03/18/2024 20:30:21

lantern-pharma-q4-2023-gaap-eps-039-beats-048-estimate
Lantern Pharma Q4 2023 GAAP EPS $(0.39) Be...
03/18/2024 20:26:22

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.48...

earnings-scheduled-for-march-18-2024
Earnings Scheduled For March 18, 2024
03/18/2024 09:57:15

Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION